Fate Therapeutics Inc (FATE) Stock
Key stats
- Market cap
- $195.12M
- Price / Earnings ratio
- -1.7x
- EPS (TTM)
- -$1.03
- Volume
- Loading
- 52-week high
- $3.23
- 52-week low
- $0.95
Source: third-party data provider, as of November 13, 2026
Compare with FATE
Recent news

Fate Therapeutics (FATE) Reports Q2 Loss, Tops Revenue Estimates
Fate Therapeutics (FATE) Reports Q2 Loss, Tops Revenue Estimates
FATE

S&P 500, Nasdaq, Dow End Higher Led By Chipmaker Stocks As Investors Look Past US-Iran Hostility — ORCL, SBUX, WULF, PANW, FATE In Focus
S&P 500, Nasdaq, Dow End Higher Led By Chipmaker Stocks As Investors Look Past US-Iran Hostility — ORCL, SBUX, WULF, PANW, FATE In Focus
FATE

FATE Stock Jumps 6% As FDA Greenlights Moving Cell Therapy To Clinical Trials
FATE Stock Jumps 6% As FDA Greenlights Moving Cell Therapy To Clinical Trials
FATE

Fate Therapeutics (FATE) Reports Q1 Loss, Misses Revenue Estimates
Fate Therapeutics (FATE) Reports Q1 Loss, Misses Revenue Estimates
FATE
Technical indicators
- RSI 14
- 30.61
- MACD 12/26/9
- -0.11
- EMA 9 of MACD
- -0.08
- MACD histogram
- -0.03
- SMA 50
- $2.20
- Price below SMA 50
- EMA 50
- $2.14
- Price below EMA 50
- SMA 200
- $1.99
- Price below SMA 200
- EMA 200
- $1.89
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 3 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

Fate Therapeutics (FATE) Reports Q2 Loss, Tops Revenue Estimates
Fate Therapeutics (FATE) Reports Q2 Loss, Tops Revenue Estimates
FATE

S&P 500, Nasdaq, Dow End Higher Led By Chipmaker Stocks As Investors Look Past US-Iran Hostility — ORCL, SBUX, WULF, PANW, FATE In Focus
S&P 500, Nasdaq, Dow End Higher Led By Chipmaker Stocks As Investors Look Past US-Iran Hostility — ORCL, SBUX, WULF, PANW, FATE In Focus
FATE

FATE Stock Jumps 6% As FDA Greenlights Moving Cell Therapy To Clinical Trials
FATE Stock Jumps 6% As FDA Greenlights Moving Cell Therapy To Clinical Trials
FATE

Fate Therapeutics (FATE) Reports Q1 Loss, Misses Revenue Estimates
Fate Therapeutics (FATE) Reports Q1 Loss, Misses Revenue Estimates
FATE

Top Cancer Stocks to Supercharge Your 2025 Portfolio
Top Cancer Stocks to Supercharge Your 2025 Portfolio
FATE

Fate Therapeutics Stock Draws Investor Attention After FDA Grants Special Designation To Its CAR T-Cell Therapy: Retail Stays Optimistic
Fate Therapeutics Stock Draws Investor Attention After FDA Grants Special Designation To Its CAR T-Cell Therapy: Retail Stays Optimistic
FATE

5 Small Cap Stocks That Popped 30% In Less than 10 Days
5 Small Cap Stocks That Popped 30% In Less than 10 Days
FATE

Billionaires Are Buying These 2 Beaten-Down Stocks. Are They Smart Buys for Your Portfolio?
Billionaires Are Buying These 2 Beaten-Down Stocks. Are They Smart Buys for Your Portfolio?
FATE

5 Cheapest Health Care Stocks You Should Think About
5 Cheapest Health Care Stocks You Should Think About
FATE

How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
FATE
About Fate Therapeutics Inc
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Bahram Valamehr M.B.A., Ph.D. | President, CEO & Director | 1977 |
| Mr. Kamal Adawi M.S., MBA | CFO & Treasurer | 1979 |
| Ms. Cindy R. Tahl J.D. | Chief Legal & Compliance Officer and Corporate Secretary | 1973 |
| Ms. Jessica Francis | Senior Vice President of Human Resources & Operations | — |
| Dr. Martin Hosking | Head of Research | — |
| Dr. Tunde Babalola Ph.D. | Senior Vice President of Technical Operations & Quality | — |
| Mr. Ryan Douglas | Senior Director of Investor Relations & Business Development | — |
| Mr. Andrew Henry | Senior Vice President of Clinical Operations | 1964 |
| Dr. Yu Cai J.D., Ph.D. | Head of Intellectual Property & Assistant General Counsel | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 30.61
- MACD 12/26/9
- -0.11
- EMA 9 of MACD
- -0.08
- MACD histogram
- -0.03
- SMA 50
- $2.20
- Price below SMA 50
- EMA 50
- $2.14
- Price below EMA 50
- SMA 200
- $1.99
- Price below SMA 200
- EMA 200
- $1.89
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
3 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $3.00
- Average
- $6.00
- High
- $8.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +2.4 | +12.2 | ||||||||||
| 2022 | -31.1 | -16.0 | +12.6 | -30.9 | -22.4 | +9.5 | +21.4 | -13.0 | -17.1 | -7.7 | -0.8 | -50.4 |
| 2023 | -41.4 | -3.9 | -6.4 | +4.5 | -20.6 | -6.1 | -14.3 | -36.8 | -24.6 | -5.7 | +29.0 | +41.1 |
| 2024 | +66.9 | +4.9 | -5.2 | -44.2 | -10.0 | -10.6 | +10.7 | |||||
| 2026 | +0.0 | +85.6 | -1.5 | -18.9 | -4.4 | -2.5 | -9.6 | -19.9 |



